Xenon Pharmaceuticals Inc (NASDAQ: XENE) kicked off on Tuesday, down -8.67% from the previous trading day, before settling in for the closing price of $33.55. Over the past 52 weeks, XENE has traded in a range of $32.70-$46.00.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Healthcare Sector giant saw their annual sales surged by 35.90% over the last five years. While this was happening, its average annual earnings per share was recorded -35.01%. With a float of $74.20 million, this company’s outstanding shares have now reached $76.42 million.
The firm has a total of 327 workers. Let’s measure their productivity. In terms of profitability, gross margin is 0.0%, operating margin of 0.0%, and the pretax margin is 0.0%.
Xenon Pharmaceuticals Inc (XENE) Insider Activity
Our next focus will be how large-scale investors are participating in this stock of the Biotechnology Industry. The insider ownership of Xenon Pharmaceuticals Inc is 3.05%, while institutional ownership is 97.30%. The most recent insider transaction that took place on Jan 24 ’25, was worth 903,214. In this transaction PRESIDENT & CEO of this company sold 22,468 shares at a rate of $40.20, taking the stock ownership to the 31,302 shares. Before that another transaction happened on Jan 27 ’25, when Company’s PRESIDENT & CEO sold 16,315 for $40.50, making the entire transaction worth $660,806. This insider now owns 31,302 shares in total.
Xenon Pharmaceuticals Inc (XENE) Earnings and Forecasts
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.99 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -35.01% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will plunge by -9.25% during the next five years compared to -14.28% drop over the previous five years of trading.
Xenon Pharmaceuticals Inc (NASDAQ: XENE) Trading Performance Indicators
Take a look at Xenon Pharmaceuticals Inc’s (XENE) current performance indicators. Last quarter, stock had a quick ratio of 17.85.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -3.01, a number that is poised to hit -0.91 in the next quarter and is forecasted to reach -4.52 in one year’s time.
Technical Analysis of Xenon Pharmaceuticals Inc (XENE)
Analysing the last 5-days average volume posted by the [Xenon Pharmaceuticals Inc, XENE], we can find that recorded value of 0.56 million was better than the volume posted last year of 0.46 million. As of the previous 9 days, the stock’s Stochastic %D was 15.20%. Additionally, its Average True Range was 1.59.
During the past 100 days, Xenon Pharmaceuticals Inc’s (XENE) raw stochastic average was set at 0.39%, which indicates a significant decrease from 1.01% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 43.28% in the past 14 days, which was higher than the 38.28% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $37.45, while its 200-day Moving Average is $39.73. Now, the first resistance to watch is $32.66. This is followed by the second major resistance level at $34.68. The third major resistance level sits at $35.72. If the price goes on to break the first support level at $29.60, it is likely to go to the next support level at $28.56. Should the price break the second support level, the third support level stands at $26.54.
Xenon Pharmaceuticals Inc (NASDAQ: XENE) Key Stats
The company with the Market Capitalisation of 2.35 billion has total of 76,543K Shares Outstanding. Its annual sales at the moment are 0 K in contrast with the sum of -234,330 K annual income. Company’s last quarter sales were recorded 0 K and last quarter income was -65,690 K.
